{"id":"W4379281954","doi":"10.1200/jco.2023.41.16_suppl.5504","title":"Patient-reported outcomes (PROs) in primary advanced or recurrent endometrial cancer (pA/rEC) for patients (pts) treated with dostarlimab plus carboplatin/paclitaxel (CP) as compared to CP in the ENGOT-EN6/GOG3031/RUBY trial.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Carboplatin; Paclitaxel; Internal medicine; Clinical endpoint; Placebo; Endometrial cancer; Randomized controlled trial; Quality of life (healthcare); Chemotherapy; Urology; Gastroenterology; Cancer; Surgery; Nuclear medicine; Cisplatin","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002519392,0.0006391603,0.001013885,0.0002748881,0.000187926,0.0004868641,0.0003544166,0.0006113199,0.001903853],"category_scores_gemma":[0.001916881,0.000193168,0.001525422,0.0003378058,0.0003412483,0.0003883566,0.0003994556,0.001373628,0.0002105875],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003037685,"about_ca_system_score_gemma":0.0004215269,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003945594,"about_ca_topic_score_gemma":0.0008849575,"domain_scores_codex":[0.9990029,0.0007364214,0.0000479935,0.00007857595,0.00006864624,0.00006552707],"domain_scores_gemma":[0.9989303,0.0003037274,0.0004867619,0.00004616969,0.00004130076,0.0001917312],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.9144177,0.002747919,0.019868,0.001282623,0.003452529,0.00006678089,0.0000786379,0.001293151,0.002346901,0.000111923,0.0009985585,0.05333528],"study_design_scores_gemma":[0.3970855,0.4067512,0.1798764,0.0002468381,0.006732609,0.0003353771,0.0001379352,0.003188056,0.001896037,0.0004848727,0.003216698,0.00004843407],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9908745,0.006353067,0.0002480617,0.0002699831,0.00007089798,0.0004451039,0.0008857335,0.00002684734,0.000825824],"genre_scores_gemma":[0.9964323,0.001190021,0.0004080815,0.0001933731,0.0000767303,0.0006271842,0.0006845227,0.00000420189,0.000383565],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002519392,"threshold_uncertainty_score":0.01332402,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1570218913015609,"score_gpt":0.4735090099771405,"score_spread":0.3164871186755796,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}